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Abstract
Objectives: To evaluate the safety and efficacy outcomes after primary percutaneous
coronary intervention (pPCI) with second-generation Resolute™ zotarolimus-eluting
stent (R-ZES) in patients enrolled in the DAPT-STEMI Trial (NCT01459627).
Background: R-ZES is one of the most used drug eluting stents worldwide. To date,
the safety and efficacy data of this stent in setting of STEMI is limited.
Methods: The Resolute-STEMI is a prespecified prospective register that reports the
safety and efficacy of R-ZES in setting of ST-Elevation Myocardial Infarction (STEMI)
at 6 months for the following endpoints: a composite endpoint of all-cause mortality,
any myocardial infarction (MI), any (unscheduled) revascularization, stroke and TIMI
major bleeding, as well as target lesion failure and stent thrombosis (ST).
Results: From a total of 1,100 STEMI patients enrolled in the trial, 998 received a
R-ZES. At 6 months the PE occurred in 42 (4.2%) patients. All-cause death, MI, revas-
cularization, stroke and TIMI major bleeding was respectively 8 (0.8%), 9 (0.8%),
34 (3.4%), 2 (0.2%), and 4 (0.4%). The rate of target lesion revascularizations involving
the culprit lesion was 1.1%. Target lesion failure was 1.5%. The rate of definite ST
was 0.5%. The rate of both definite or probable ST was 0.7%.
Conclusions: The present analysis is the largest to date reporting short-term and
mid-term clinical outcomes with the R-ZES stent in setting of STEMI. At 30 days and
6-months R-ZES has an outstanding safety and efficacy even in this high-risk cate-
gory of patients.
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1 | INTRODUCTION
Revascularisation of the acutely occluded vessel by means of primary
percutaneous coronary intervention (pPCI) has evolved as the gold stan-
dard treatment for patients presenting with ST-elevation myocardial
infarction (STEMI). Clinical outcomes, after stenting of the occluded
coronary lesion with second-generation rapamycin-like eluting drugs
from biocompatible durable-polymers are superior in terms of safety
and efficacy as compared to bare metal stents and first generation
paclitaxel-eluting stents.1–3 Zotarolimus-eluting stent has evolved as
one of the most used stents worldwide as clinical trials have shown that
this device is at least as good as the most studied second-generation
DES, the everolimus-eluting stent. Indeed, the Resolute All Comers- as
well as the Twente Trial, showed true noninferiority between these
two devices.4,5 Furthermore, sub-analyses of both these trials in STEMI
patients, have shown both noninferiority between these devices,6 how-
ever to date, no large-scale prospective data regarding safety and effi-
cacy of Resolute™ Zotarolimus-eluting stent (R-ZES) in setting of pPCI
for STEMI patients have been published. Therefore, we present the
results of Resolute-STEMI; a prospective international register, a
prespecified analysis of the DAPT-STEMI trial,7 which represents the
largest study cohort to date regarding safety and efficacy of R-ZES in
setting of STEMI.
2 | MATERIALS AND METHODS
2.1 | Study design
The DAPT-STEMI trial was a prospective, randomized, international
open label trial testing the hypothesis that 6 months of dual anti-
platelet therapy (DAPT) after second generation R-ZES implantation,
in the setting of pPCI for STEMI, is not inferior to 12 months DAPT
(noninferiority hypothesis), in terms of a combined endpoint of safety
and efficacy. The design of the DAPT-STEMI trial has already been
published.7 Briefly, patients that underwent pPCI with R-ZES in the
setting of STEMI were enrolled and if event-free at 6 months were
randomized (1:1 fashion) between single antiplatelet therapy (SAPT;
aspirin only) versus DAPT for an additional 6 months and followed
until 2 years after pPCI as shown in Figure 1. The primary end point
(PE) of the trial is a patient oriented composite endpoint of all-cause
mortality, any myocardial infarction, any revascularization, stroke and
major bleeding (NACCE) at 18-months after randomization. All
enrolled patients were followed until 6 months when the randomiza-
tion took place for event-free patients. All patients gave informed
consent for the procedure and approval of the ethics committee was
obtained.
The results of the entire study population till 6 months represent a
prespecified study: the Resolute-STEMI register (see Figure 1). R-ZES
was strongly recommended in the DAPT-STEMI trial however in case of
specific size availability other modern generation DES could be used. For
the purpose of the RESOLUTE-STEMI, only patient treated with R-ZES,
were included. R-ZES is a cobalt-chromium stent with a strut thickness
of 89 μm that elutes zotarolimus, a semi-synthetic rapamycin derivative
from a three blend composed biocompatible durable polymer coating.
2.2 | Procedures and treatment
STEMI patients between 18 and 85 years who underwent pPCI with a
second-generation R-ZES were enrolled. At inclusion, all STEMI
patients were treated according to standard clinical practice. Artery
puncture site was left to the discretion of the operator, although radial
approach was strongly recommended. Thrombosuction and/or
predilatation of the lesion was left to the discretion of the operator.
DAPT, consisting of aspirin (ASA) 150–300 mg per os or 250–500 mg
bolus intravenous (i.v.) followed by 75–100 mg daily, and prasugrel
60 mg loading dose, followed by 10 mg daily, or ticagrelor 180 mg
loading dose, followed by 90 mg twice daily were initiated and contin-
ued for 6 months. Patients treated with clopidogrel received a 600 mg
loading dose followed by 75 mg daily for 6 months. Additional (sched-
uled) revascularisations in nonculprit lesions, when needed, were per-
formed within 45 days from the pPCI, however, even in this case the
6 month follow-up time point is based on the date of the pPCI.
F IGURE 1 Flowchart of RESOLUTE
STEMI and DAPT STEMI. CABG,
coronary artery bypass graft; DES, drug-
eluting stent; PCI, percutaneous coronary
intervention; STEMI, ST-elevation
myocardial infarction; ZES, zotarolimus-
eluting stent [Color figure can be viewed
at wileyonlinelibrary.com]
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2.3 | Patient follow-up, data collection, and
evaluation
Patients were enrolled and follow-up visits took place at discharge,
30 days and 6 months, either by regular clinical visits or telephone.
Clinical condition of the patient was evaluated, and adverse clinical
events were recorded. Monitoring and event adjudication was per-
formed by an independent clinical event committee (Diagram BV, inde-
pendent clinical research organization, Zwolle, the Netherlands).
2.4 | Resolute-STEMI endpoints and definitions
The primary outcome of the Resolute-STEMI was a patient oriented
composite endpoint of all-cause mortality, any myocardial infarction
(MI), any (unscheduled) revascularisation, stroke and Thrombolysis In
Myocardial Infarction (TIMI) major bleeding,8 the net major adverse
cardiac and cerebrovascular events (NACE) at 6 months. MI were
adjudicated based on the ARC definition.9 Any revascularization was
defined as any clinically indicated revascularisation procedure by PCI
or CABG not foreseen at randomization. The major secondary end-
point was the outcome of the primary endpoint at 30 days, other sec-
ondary endpoints were the occurrence of definite and probable stent
thrombosis (ST) as well as target lesion failure (TLF) at 30 days and
6 months respectively. Definite or probable ST were defined
according to the Academic Research Consortium (ARC) criteria.9 TLF
was defined as the composite of cardiac death, target-vessel MI and
any target lesion revascularization (TLR). Stroke was defined as an
acute neurological event lasting at 24 hr, with focal signs and symp-
toms, which requires confirmation by computed tomography (CT),
magnetic resonance imaging (MRI), or pathological confirmation.
2.5 | Statistical analysis
Baseline characteristics were presented as mean ± standard deviation
for continuous parameters and as numbers and percentages for nomi-
nal variables. The incidence of the primary and secondary endpoints
were calculated by means of Kaplan Maier estimates. Analyses were
performed using the SPSS version 25.0 software (SPSS Inc., Chi-
cago, IL).
3 | RESULTS
From a total of 1,100 STEMI patients enrolled in the trial, 998 received
a R-ZES. Baseline characteristics of the study population receiving R-
ZES are reported in Table 1. Mean age was 60 (SD ± 10.6) years, with
a predominance of male gender (76%), strikingly half of the population
were active smokers. Majority of the patients received clopidogrel
(43%), followed by ticagrelor (29%), and prasugrel (28%). In 42%
patients the left anterior descending artery (LAD) was the culprit ves-
sel. The number of stents for the culprit lesion per patient was 1.28
± 0.60 with a length of 26.1 ± 12.8 mm. Nonculprit PCI was
performed in 14% of patients. For 72% of the patients the minimum
stent diameter was at least 3 mm.
Clinical outcomes at 30 days and 6 months are shown in Table 2.
Clinical follow-up was obtained in 98% of patients in the present
TABLE 1 Baseline characteristics
N = 998
Patient characteristic
Age—years 60.0 ± 10.5
Male gender 760/998 (76%)
Body-mass index (kg/m2) 27.7 ± 4.4
Medical history
Prior CABG 11/998 (1%)
Prior PCI 51/998 (5%)
Prior myocardial infarction 53/998 (5%)
Stroke or TIA 26/998 (3%)
Peripheral arterial disease 29/998 (3%)
Congestive heart failure 40/998 (4%)
Risk factors
Diabetes mellitus 133/998 (13%)
Hypertension 447/998 (45%)
Dyslipidaemia 273/998 (27%)
Current cigarette smoker 484/998 (49%)
Family history of CAD 337/998 (34%)
Medication at start of study
Thienopyridine
Clopidogrel 434/998 (43%)
Prasugrel 276/998 (28%)
Ticagrelor 285/998 (29%)
Percutaneous coronary intervention
Infarct related artery
LM 4/998 (0.4%)
LAD 417/998 (42%)
RCA 398/998 (40%)
LCX 179/998 (18%)
ACC-AHA type B2 357/998 (36%)
ACC-AHA type C 226/998 (23%)
No. of stents total (culprit lesion) 1.28 ± 0.60
Total stent length total––mm (culprit lesion) 26.1 ± 12.8
Nonculprit PCI 139/998 (14%)
Minimum stent diameter
<2.5 mm 68/1276a (5%)
2.5–3.5 mm 1091/1276 (86%)
>3.5 mm 117/1276 (9%)
aThe total number of stents used for culprit lesion during index procedure.
CAD, coronary artery disease; CABG, coronary artery bypass graft; DAPT,
dual antiplatelet therapy; LAD, left anterior descending; PCI, percutaneous
coronary intervention; RCA, right coronary artery; RCX, right circumflex
artery; SAPT, single antiplatelet therapy; STEMI, ST-segment elevated
myocardial infarction; TIA, transient ischemic attack.
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registry. The primary endpoint was reached by 42 (4.2%) patients.
Eight patients died of which 7 (0.7%) because of a cardiac reason. TLF
occurred in 1.5% of the patients. TVR occurred in 16 (1.6%) of the
patients, with 11 (1.1%) patients needing TLR and 5 (0.5%) needing
non-TLR TVR. The incidence of definite or probable ST at 6 months
was 0.7%, of which 0.5% was early and 0.2% was late, respectively,
according to the ARC definition.9
4 | DISCUSSION
The present study, which represents the largest study cohort dedi-
cated to the evaluation of the safety and efficacy of R-ZES in setting
of STEMI, showed a low rate of NACCE in STEMI patients treated
with 1 or more R-ZES, with the primary endpoint occurring in 4.2% of
patients at 6 months.
Furthermore, the rate of ST (definite or probable) was very low,
with an incidence of 0.7% at 6 months, confirming an outstanding
device outcome even in this high-risk category of patients.
Only few data regarding clinical outcomes of STEMI patients
treated with this second generation stent are available: 122 STEMI
patients in the RESOLUTE All Comers6 and a total of 371 STEMI
patients in the RESOLUTE Global Clinical Trial Program (including
RESOLUTE International,10 RESOLUTE China Randomized Controlled
Trial,11 and RESOLUTE China Registry).12 Therefore the sample size
of our analysis, significantly enriches the actual knowledge of out-
comes in STEMI patients treated with second generation R-ZES.
Indeed, R-ZES is a widely used DES in all-comer patients and this anal-
ysis confirmed that it can be used efficiently and safely in STEMI
patients as well.
Rates of early definite and probable ST were similar to those
found in the RESOLUTE All Comers clinical trial,6 with 0.8% in that
trial versus 0.5% in our trial. The RESOLUTE Global Clinical Trial Pro-
gram found showed slightly higher rates of early ST of 2.0%,10–12 in
the Twente trial, the incidence of early ST was 0.2% in patients receiv-
ing a R-ZES, however STEMI patients were excluded.4 The low rate of
adverse events with this second-generation stent may be the result of
improvement of the stent characteristics like thinner stent struts as
well as the use of a biocompatible polymer.
Indeed, thinner stent struts favor a better and homogeneous
endothelial strut coverage as compared to the thicker stainless steel
struts of the first-generation DES,13 and DES with thin struts have
shown a low risk of adverse cardiovascular events in patients with a
variety of clinical syndromes.14 The R-ZES uses a biocompatible dura-
ble polymer that enables longer drug elution and has shown to signifi-
cantly affect the amount of neointima compared with the previous
zotarolimus-eluting platform.15 Moreover, OCT studies have demon-
strated essentially complete endothelial coverage at 3 months with
this device.16
Thus, the low event rates in-patient with myocardial infarction
treated with PCI with the second-generation stent as compared to
first-generation DES, might be attributed to the improved design of
these devices.17
Moreover it has been shown that patients who discontinued
DAPT between 1 and 12 months after implantation of the R-ZES had
low rates of ST and adverse cardiac outcomes18 and recently the
DAPT STEMI trial provided an important answer regarding the nonin-
feriority of 6 months of DAPT compared to 12 months DAPT after R-
ZES implantation in the setting of pPCI for STEMI.19 Indeed 6-month
DAPT was noninferior in a patient-oriented composite clinical end-
point versus the regimen of 12 months DAPT showing that a shorter
DAPT duration is also feasible and safely applicable if clinically
required in STEMI patients who received a R-ZES.
5 | CONCLUSIONS
The present analysis is the largest to date reporting outcomes with
the R-ZES stent in STEMI patients. At 30-days and 6-months, the
Resolute-STEMI Prospective Registry confirmed that the safety and
the efficacy of this device is outstanding even in this high-risk cate-
gory of patients.
TABLE 2 Clinical outcome at 30-days and 6 months
30 days
N = 998
6 months
N = 998
Primary endpoint
Composite of all-cause mortality, any MI, any
revascularization, stroke and TIMI major
bleeding (net adverse clinical events)
15 (1.5%) 42 (4.2%)
Secondary endpoints
Composite of all-cause mortality, any MI,
stent thrombosis, stroke and TIMI major
bleeding
10 (1.2%) 20 (2.0%)
Death 6 (0.6%) 8 (0.8%)
Cardiac 6 (0.6%) 7 (0.7%)
Stroke 0 1 (0.1%)
Myocardial infarction 4 (0.4%) 9 (0.9%)
Definite stent thrombosis 3 (0.3%) 5 (0.5%)
Probable stent thrombosis 2 (0.2%) 2 (0.2%)
Possible stent thrombosis 0 1 (0.1%)
Target lesion failurea 9 (0.9%) 15 (1.5%)
Revascularization 13 (1.3%) 34 (3.4%)
Target vessel (TVR) 7 (0.7%) 16 (1.6%)
Target lesion (TLR) 6 (0.6%) 11 (1.1%)
Target vessel, nontarget lesion (non-TLR
TVR)
1 (0.1%) 5 (0.5%)
Nontarget vessel (non-TVR) 6 (0.6%) 18 (1.8%)
Bleeding
TIMI major 0 4 (0.4%)
BARC type 3 0 4 (0.4%)
Note: Data are presented for the intention-to-treat population. BARC,
bleeding academic research consortium; MI, myocardial infarction; TIMI,
thrombolysis in myocardial infarction.
aTarget lesion failure is defined as cardiac death, target lesion
revascularization, or target lesion myocardial infarction.
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6 | LIMITATIONS
This prespecified sub-analysis had some limitations, that have to be
addressed. Firstly, it has the general intrinsic limitations of a prospec-
tive registry. Secondly, no standard coronary angiography was per-
formed at follow-up, however, clinically relevant stent related
outcomes were addressed in the registry. Finally, per protocol, the
choice of the P2Y12 inhibitor prescribed was at the operators' discre-
tion reflecting the ESC guidelines at the time when this trial was
designed. However, potential differences in outcomes between
patients treated with different P2Y12 inhibitors can only be appreci-
ated in studies with much larger size than our present trial.
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